December 09, 2020
HOW CYTOAGENTS’ PLANS FOR GROWTH RUN FAR BEYOND COVID CRISIS
GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said.